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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYGlioblastoma (GBM) is an aggressive brain tumor whose growth is driven by stem cell-like cells. BMP signaling triggers cell-cycle exit and
differentiation of GBM stem cells (GSCs) and, therefore, might have therapeutic value. However, the epigenetic mechanisms that accom-
panydifferentiation remainpoorlydefined. It is alsounclearwhether cell-cycle arrest is terminal.Herewefindonly a subset ofGSCcultures
exhibit astrocyte differentiation in response to BMP. Although overtly differentiated non-cycling astrocytes are generated, they remain
vulnerable to cell-cycle re-entry and fail to appropriately reconfigure DNAmethylation patterns. Chromatin accessibilitymapping identi-
fied loci that failed to alter in response to BMP and these were enriched in SOX transcription factor-bindingmotifs. SOX transcription fac-
tors, therefore, may limit differentiation commitment. A similar propensity for cell-cycle re-entry and de-differentiation was observed in
GSC-derived oligodendrocyte-like cells. These findings highlight significant obstacles to BMP-induced differentiation as therapy for GBM.INTRODUCTION
Many solid tumors display phenotypic and functional
cellular heterogeneity reminiscent of normal tissues
(Shackleton et al., 2009). An underlying developmental
hierarchy therefore may exist, with a subset of malignant
stem cell-like cells generating more differentiated non-
malignant progeny. Ifmalignant stem cells could be perma-
nently forced into a non-proliferative and terminally
differentiated state, then differentiation therapy might be
highly effective.
Glioblastoma (GBM) is one of themost aggressive human
cancers. GBMs contain distinct cellular subpopulations ex-
pressing neural stem (NS) and progenitor cell markers (e.g.,
NESTIN, SOX2, OLIG2, ASCL1, and FOXG1) (Dahlstrand
et al., 1992; Singh et al., 2004; Suva` et al., 2014; Verginelli
et al., 2013). Isolation and orthotopic xenotransplantation
of GBM stem cells (GSCs) has confirmed their tumor-initi-
ating potential (Singh et al., 2004). GBMs also harbor
cells expressing markers associated with differentiated glial
lineages (e.g., O4- and MBP-expressing oligodendrocytes
or GFAP-expressing astrocytes). Astrocytes and oligoden-
drocytes are post-mitotic under normal homeostasis, but
whether GSCs can generate terminally differentiated prog-
eny remains a significant unresolved issue.Stem Cell RBMP signaling triggers cell-cycle exit and astrocyte differ-
entiation of NS cells (Bonaguidi et al., 2005). Exposure of
GBM-derived stem cells to BMP4 can drive astrocyte differ-
entiation both in vitro and in vivo (Piccirillo et al., 2006),
raising the prospect that this pathway could be exploited
for differentiation therapy. It is assumed that GBM stem
cell differentiation follows a unidirectional path; indeed,
a gene regulatory network that defines the tumor-initiating
state and distinguishes non-tumorigenic astrocytes has
been defined recently (Suva` et al., 2014). There are, how-
ever, many key unresolved questions. Can BMP induce a
consistent differentiation response widely across the spec-
trum of GBMs? Is astrocyte differentiation accompanied
by extensive transcriptional and epigenetic modifications,
and do these mirror normal NS cell differentiation? Are
epigenetic gene regulatory mechanisms, such as DNA
methylation or chromatin remodelling, able to stably sup-
press pro-tumorigenic pathways? Can differentiation cues
trigger a permanent cell-cycle arrest?
Here we use primary human GBM-derived NS (GNS) cell
cultures as a tractable and disease-relevant experimental
model to determine the transcriptional and epigenetic
changes accompanying differentiation. We assessed longi-
tudinal genome-wide DNA methylation changes, chro-
matin accessibility, and the stability of the differentiatedeports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 The Authors 829
phenotype. Our findings highlight several important
caveats that may undermine the utility of BMP signaling
for the treatment of GBM.RESULTS
GNS Cell Lines Display Diverse Responses to
Differentiation Cues
We first assessed differentiation responses in a panel of six
previously reported GNS cell lines obtained from inde-
pendent patient tumors (Pollard et al., 2009; Fael Al-May-
hani et al., 2009), which mirror the transcriptional sub-
types of primary GBM (Figure S1A). Growth factor (GF)
withdrawal from culture media typically results in sponta-
neous multi-lineage differentiation of GNS cells, with a
subpopulation of cells undergoing cell-cycle exit (Pollard
et al., 2009). However, a more pronounced and uniform
astrocyte differentiation response is observed following
7 days of BMP4 treatment and GF withdrawal (no EGF
or FGF-2).
Each of the six GNS cell lines tested displayed reduced
proliferation in response to BMP to a greater extent than
GF withdrawal alone, confirming the cytostatic effects
of BMP signaling (Figure 1A). However, consistent with pre-
vious reports (Lee et al., 2008), we also observed clear
variability between GNS cell lines in the degree of the
BMP-induced cytostatic response and the proportion of
cells that activated GFAP expression (Figure 1B). GNS cell
lines G19 and G26 exhibited uniform upregulation of the
astrocyte marker GFAP, whereas G144 and G166 failed to
efficiently upregulate GFAP (Figure 1B). EdU incorporation
assays and immunocytochemistry for the cell cycle marker
MCM2 confirmed that >80% of cells were driven out of the
cell cycle in G19 and G26 following 8 days of continuous
BMP treatment (Figures 1B–1D). Thus, BMP does not effec-
tively induce astrocyte differentiation across all patient-
derivedGNS cell lines. Only inG19 andG26 didwe observe
a robust cytostatic astrocyte differentiation response
similar to genetically normal NS cell controls. Levels of
BMPR1B expression may explain the differential responses
observed in these two GSC lines, as reported previously
(Lee et al., 2008); we found BMPR1B mRNA at >10-fold
higher levels in G19 and G26 compared to other lines (Fig-
ure 1E). G19 and G26 therefore were used in subsequent
experiments to explore transcriptional and epigenetic
changes in differentiating astrocytes.BMP-Induced Transcriptional Changes Continue to
Accrue overManyWeeks in Post-mitotic GBM-Derived
Astrocytes
To first delineate the kinetics of transcriptional changes
associated with the response to BMP4, we initially assessed830 Stem Cell Reports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 ThemRNA expression of key markers over a time course of 8,
16, 32, and 48 days in G26. As anticipated, the NS cell-asso-
ciated markers OLIG2 and EGFR genes were rapidly down-
regulated following 8 days of BMP-4 treatment; astrocyte
markers GFAP and AQP4, as well as the BMP-signaling
genes ID1–3, were upregulated (Figure 2A). However, we
also noted continuous changes in levels of expression
over the entire time course, up until 48 days. Similarly,
slow kinetics of transcriptional change were observed by
Taqman low-density array assays for a set of 72 genes that
we had identified previously as candidate regulators of
oncogenic pathways in GBM (Engstro¨m et al., 2012; Fig-
ure 2B). Thus, while cell-cycle exit and morphological
changes occur rapidly in response to BMP treatment, there
is also a slower accumulation of additional transcriptional
changes that accrue over the course of weeks and months.
These might be indicative of an epigenetic progression or
epigenetic switching (i.e., a slow directional change until
threshold or switch point is reached), which may be
required for stabilization of the differentiated state. These
later time points (32 and 48 days) therefore were included
in the profiling of DNA methylation patterns described
below.
BMP-Induced Astrocyte Differentiation Is
Accompanied by Delayed or Incomplete
Reconfiguration of DNA Methylation Patterns in
GNS Cells
Patterns of DNA methylation frequently are reconfigured
during stem cell differentiation to stabilize and safeguard
the differentiated state. Altered DNA methylation is,
accordingly, a plausible molecular mechanism that could
function in differentiating tumor stem cells to silence
oncogenic pathways (Care´n et al., 2013). We therefore first
assessed whether G19 and G26 displayed methylation pro-
files in proliferating cultures prior to BMP treatment that
were disease relevant. DNA methylation profiles across a
panel of 13 different GNS cell lines were defined using
the HumanMethylation450 BeadChips, and they were
compared to data from primary tumors attained using the
same platform as the Cancer Genome Atlas (TCGA). All
GNS cells used in this study were found to display patterns
of DNA methylation similar to primary GBM tumors (Fig-
ure S1B). None of the GNS cell lines displayed a glioma-
CpG island hypermethylator phenotype (G-CIMP), which
is a feature of secondary GBM. G19 and G26 cell cultures
therefore harbor DNA methylation patterns similar to
those of primary GBM tumors.
We next defined patterns of DNA methylation across a
48-day time course in post-mitotic BMP-induced differenti-
ating astrocytes derived from G19, G26, plus normal refer-
ence NS cell controls. Surprisingly, few methylation vari-
able positions (MVPs) accumulated in the first 8–16 days,Authors
Figure 1. BMP Treatment Reduces Proliferation of GNS and NS Cells
(A) Proliferation curves of seven GNS and two NS cells (NS-1 and NS-2). At day 7 all paired comparisons (GF versus BMP4) showed a
significant difference in proliferation rate (p < 0.01).
(B) Cells were expanded in the GFs EGF and FGF-2 (GF) or exposed to BMP4 in the absence of GFs for 8 days (BMP). Proliferation was assessed
by EdU (16 hr incorporation) and astrocyte differentiation using GFAP (red).
(C) Quantification of EdU-positive cells in proliferating conditions (GF), GF withdrawal (GF), and BMP4 is shown.
(D) Immunostaining for cell-cycle marker MCM2 (red) and quantification (bottom) are shown.
(E) Relative mRNA expression levels of the BMPR1B in NS and GNS cell lines (fold change relative to normal brain). Error bars denote SD of
two technical and two biological replicates for (C)–(E) (triplicates for immunostainings). Scale bars in (B) and (D), 100 mm.and the vast majority emergedmore slowly over a period of
many weeks for each cell line, including normal NS cells
(Figures 2C and 2D). Thus, we did not observe rapid wide-
spreadDNAmethylation changes associatedwith astrocyte
differentiation (within days), as has been described for the
hematopoietic lineage (Ji et al., 2010).
MVPs were enriched at enhancers and gene bodies,
consistent with a role in transcriptional regulation (Fig-
ure 3A), and we only rarely identified MVPs that reverted
over the 48-day time course (<1% of probes in G26). There
were no significant directional global changes in non-CpG
methylation or hydroxymethylation, which is consistent
with the observed gain of methylation (data not shown).Stem Cell RControls grown under normal self-renewal conditions
(plus EGF and FGF-2; without BMP) for 48 days showed
no significant alterations in methylation compared to
day 0 samples.
In G26, MVPs accumulated increasingly with the dura-
tion of BMP exposure at genes associated with neuronal
and astrocyte differentiation, such as GRIK2 and S100A6,
respectively (Figure 3B). Additionally, consistent with an
appropriate differentiation response, gene ontology (GO)
terms such as neurogenesis and cell differentiation
emerged as statistically enriched in the set of 2,325 genes
(with MVPs of more than 30% alteration in methylation
frequency) (Figure 3C).eports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 The Authors 831
Figure 2. Kinetics of DNA Methylation Changes Induced by BMP in NS and GNS Cells
(A) The qRT-PCR analysis of G26 during a 48-day time course of BMP treatment. Error bars denote SD of four independent experiments
(technical and biological duplicates).
(B) A panel of 72 genes, previously defined as differentially expressed between GNS and NS cells (Engstro¨m et al., 2012), was analyzed
using Taqman low-density arrays on G26 cells treated for up to 48 days with BMP4.
(C) Total numbers of identified MVPs during BMP treatment for GNS cell lines (G19 and G26) and normal NS cells (NS-1) at each time point
(BMP 8–48 days; B8, B16, B32, B48) are shown.
(D) Dendrogram shows the 450K methylation array data.We also identified enrichment of polycomb repressor
complex 2 (PRC2) target genes (Figure 4D), particularly
CpG island/shore/shelf regions for G26 and NS-1 (p <
0.001) (Figure 3A). A set of GBM MVPs that are associated
with primary GBM tumors, but not low-grade tumors or
normal neural cell types, was compiled from published
datasets (see Experimental Procedures). Approximately
12% of these sites, including those associated with SFRP2,
a WNT-signaling pathway antagonist, were altered in
response to BMP in G26 (Figure 3D). These data are consis-
tent with G26 cell responses to BMP involving progression
to a differentiated and less malignant state.832 Stem Cell Reports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 TheDespite the above observations, we noted that DNA
methylation changes were delayed in G26 compared to
normal NS cells (Figure 2C). Also, for G19 we identified
only limited numbers of MVPs (<500 compared to >5,000
for NS and G26), even after 48 days of BMP treatment (Fig-
ure 2C). Thus, we observed an incomplete acquisition of
altered DNA methylation patterns during the differentia-
tion response for G19. Together these data indicate that,
even within the subset of GNS cells that display strong
cytostatic responses to BMP, there is a failure to rapidly
and fully reconfigure differentiation-associated patterns
of DNA methylation.Authors
Figure 3. Analysis of Sites of DNA Methylation Alterations Imposed by BMP Treatment
(A) Percentage enrichment of epigenomic features (left), enhancers (middle), and PRC2 target genes (right) is shown (random resampling
p value% 0.001).
(B) Visualization of MVPs over the time course of BMP is shown for the following: the astrocyte marker S100A6, the neurotransmitter
receptor GRIK2, and the WNT-signaling tumor suppressor gene SFRP2.
(C) GO analysis for the significantly altered MVPs with >30% change in methylation were analyzed using DAVID (GO BP_ALL).
(D) Publicly available methylation datasets for pilocytic astrocytoma and human brain orbitofrontal cortex (non-neuronal) were used to
generate a set of GBM-specific MVPs (top 100 MVPs shown), and these sites are shown for the BMP-treated GNS cells. Each experiment
represents biological and technical duplicates of each sample.BMP Signaling Fails to Silence Transcription of
Cell Cycle and DNA Replication Licensing Genes in
GNS Cells
The large number of MVPs detected in G26 following BMP
treatment prompted us to assess genome-wide transcrip-
tional changes using RNA sequencing (RNA-seq). We
confirmed that MVP-associated genes, S100A6, GRIK2,
and SFRP2, displayed altered gene expression patterns in
the expected direction (Figure 4A). As anticipated, astrocyteStem Cell Rmarker genes GFAP, AQP4, and ALDH1A1 (Adam et al.,
2012) also were upregulated, as were components of the
BMP-signaling pathway, such as SMADs and IDs.
Cluster analysis of mRNA expression also suggested two
phases of transcriptional change, the first occurring as a
rapid immediate response to BMP and a second occurring
slowly over subsequent weeks, mirroring the time course
of DNA methylation changes (Figures 4B and 4C). The
most significantly downregulated genes in BMP-treatedeports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 The Authors 833
Figure 4. RNA-Seq Analysis of BMP4-Treated G26 and NS-1 Cells
(A) Gene expression of the MVP-associated genes GRIK2, SFRP2, and S100A6 (left) and the two top downregulated genes OLIG1 and OLIG2
(right). Fold change of the average of the number of reads in the two passages is shown.
(B) Dendrogram of the RNA-seq data is shown.
(C) The mRNA expression levels for many PRC2 target genes are frequently altered during BMP treatment.
(D) The mRNA levels for FOXM1 and PLK1 are shown.
(E) Heatmap shows transcription factors associated with the tumor-propagating state that recently was defined (Suva` et al., 2014).
(F) Gene expression of DNA replication licensing proteins and cell-cycle regulators is shown relative to growth factors (GF) at day 0.
(G) Quantification of MCM2-positive cells from immunocytochemistry. Each experiment represents biological and technical duplicates of
each sample. Error bars denote SD of replicates.G26 cells were the well-studied NS cell regulators, OLIG1
(fold change 570, adjusted p value 6.6E52) and OLIG2
(165-fold, adjusted p value 9.5E42) (Figures 4A and
4E). Expression of many other PRC2 target genes also
was altered, such as HES5, and components of the
WNT-signaling pathway (WNT1, WNT5A, and FRZB)
(Figure 4C). GO terms such as cell differentiation and
nervous system development were identified in this set
(data not shown). We also observed BMP-induced sup-
pression of mRNA levels for many of the transcription
factors that define the core gene regulatory network834 Stem Cell Reports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 Therecently defined for GBM stem-like cells (Suva` et al.,
2014; Figure 4E).
In G26, themajority of gene expression changes entailed
an increase in expression level, whereas both upregulated
and downregulated genes were detected in NS cells; this
suggests a failure to appropriately silence genes in G26
(data not shown). This set of failed silencing genes included
many DNA replication licensing proteins and cell-cycle
regulators, including the mini-chromosome maintenance
proteins (MCMs); CDT1; proliferating cell nuclear antigen
(PCNA, a co-factor of DNA polymerase delta); MYBL2,Authors
involved in cell-cycle progression; and mitotic regulators
FOXM1 and PLK1 (Figure 4F). We also confirmed this at
the protein level using immunocytochemistry analysis of
MCM2 (Figure 4G). Thus, while BMP can impose appro-
priate transcriptional changes associated with BMP-
induced differentiation, there is incomplete silencing of
expression of the genes involved in competence for cell-cy-
cle re-entry.
GBM-Derived Astrocyte-like Cells Do Not Undergo
Terminal Cell-Cycle Arrest
Stem cells within tissues that turn over rapidly, such as
blood and skin, generate terminally differentiated progeny
with a limited lifespan; differentiation therapy therefore
can eradicate proliferating tumor cells (e.g., in acute pro-
myelocytic leukemia [APL]; Sell, 2004). By contrast, in the
nervous system astrocytes and oligodendrocytes are long-
lived, and thus any differentiation therapy for GBM must
ensure that differentiation is accompanied by robust sup-
pression of proliferative potential.
While the majority of astrocytes in the adult brain are
post-mitotic, the quiescent NS cell population in the adult
subependymal zone displays astrocytic features, including
GFAP expression (Doetsch et al., 1999). Additionally, under
certain injury conditions, GFAP-expressing astrocytes can
be proliferative (e.g., reactive gliosis). GFAP also is ex-
pressed by radial glia progenitors during fetal development.
Hence, whether GFAP-expressing astrocytes induced
following BMP treatment of GNS cells are irreversibly
cell-cycle arrested or in a quiescent/G0 state has not yet
been resolved. Failure to fully silence expression of DNA
replication licensing components and incomplete reconfi-
guration of DNA methylation patterns prompted us to
test if GNS cell-derived astrocytes are terminally cell-cycle
arrested or instead driven to a transcriptional state with
hallmarks of quiescent astrocyte stem cells.
Limited detection of MCM2 protein and EdU incorpora-
tion in the majority of the G26 cells in BMP-treated cul-
tures, and failure of significant increases in cell numbers
throughout the 48-day time course, suggested that BMP-
treated G26 cells had withdrawn from cell cycle or were
slow cycling (Figure 1A). To test whether proliferative po-
tential was irrevocably lost, we tested the consequences
of re-exposing non-cycling and overtly differentiated astro-
cytes to GFs (i.e., self-renewal conditions EGF and FGF-2,
with no BMP). We found that, despite the extended time
in a non-cycling state at both early and late stages of differ-
entiation (7 or 54 days of BMP treatment), GNS cells
immediately began proliferating rapidly again (Figures 5A
and 5B). GNS cell-derived astrocytes are, therefore, not
terminally cell-cycle arrested; they are able to readily re-
enter the cell proliferation cycle upon withdrawal of differ-
entiation stimulus.Stem Cell RWe next assessed DNA methylation patterns and differ-
entiation markers in the astrocytes that re-entered cell cy-
cle. GFAP and AQP4mRNA were markedly downregulated,
but not fully extinguished, within 4 days (Figure 5C), indic-
ative of partial de-differentiation. This contrasts with the
response in NS cells, where GFAP expression remained sta-
ble (and increased) after the 4 days (Figure S2). Transcrip-
tion of OLIG2 and EGFR, two key regulators of the NS cell
state, was increased, although it did not reach NS cell levels
(Figure 5C). DNA methylation analysis indicated that,
despite cell-cycle re-entry, the patterns of DNA methyl-
ation were not immediately reverted to the original stem
cell state (Figure 5D). Together these data indicate that
BMP-induced astrocytes remain capable of rapidly re-
engaging in cell cycle, even after many weeks in a non-pro-
liferative post-mitotic state, and they undergo a partial de-
differentiation. Differentiated astrocytes therefore are not
permanently driven to a terminally differentiated cell-cycle
arrested state by BMP treatment, and they remain vulner-
able to reacquisition of a proliferative stem cell-like state.
BMP4-Treated GNS Cells Remain Tumor Initiating
We next assessed whether BMP-treated cells remain tumor-
igenic. We performed orthotopic transplantation of the
following: untreated G26 cells, BMP-treated G26 cells
(either 7 or 54 days), and BMP-treated cells that were subse-
quently re-exposed to EGF and FGF-2 for 4 days (prior to
transplantation). Cells were injected into the ventral fore-
brain of immunocompromised mice and we then moni-
tored overall survival. BMP-treated cells did not show any
significant increase in survival times (Figure 5E), suggesting
that terminal differentiation of the cells is not achieved
and the transplanted population is readily able to generate
tumors.
Chromatin Accessibility Mapping Reveals SOX Motif-
Enriched Regions that Fail to Close in BMP-Treated
GNS Cells
We hypothesized that the failure of GNS cells to undergo
differentiation commitment in response to BMP might
result from an inappropriate chromatin remodelling at
gene regulatory regions, such as enhancers. The assay for
transposase-accessible chromatin using sequencing
(ATAC-seq) provides a powerful method for defining chro-
matin compaction and nucleosome positioning genome-
wide (Buenrostro et al., 2013). We used this technique to
define in an unbiased manner whether genomic regions
in GNS cells failed to be silenced relative to NS cells after
8 days of BMP treatment. Principal component analysis
(PCA) confirmed significant BMP-induced chromatin re-
modelling in both GNS and NS cells (Figure 6A). To deter-
mine any regions of incomplete silencing specific to GNS
cells, we identified differentially accessible regions thateports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 The Authors 835
Figure 5. BMP-Treated Cells Do Not Undergo Terminal Differentiation
(A) G26 under self-renewal conditions (GF), treated with BMP4 for 7 (B7) and 54 days (B54), and when adding back GFs after the respective
treatment times for 4 days (B7 + GF4 and B54 + GF4) is shown.
(B) Quantitation of EdU-positive cells from (A). Error bars denote SD of five technical replicates. Student’s two-sided t test was used for
pairwise comparisons (*p% 0.05).
(C) The qPCR analysis of G26 to determine the effects of re-exposure to GFs on astrocyte markers (AQP4 and GFAP) and NS cell-associated
markers (EGFR, SOX2, and OLIG2). Error bars denote SD of two technical replicates from two biological replicates relative to cultures in GFs
at day 0.
(D) Dendrogram shows the 450K methylation data in G26 before and after the readdition of EGF and FGF-2 for 4 days (GF).
(E) Kaplan-Meier curve showing survival data of mice transplanted with G26 grown under self-renewal conditions (GF), treated with BMP4
for 7 (B7) and 54 days (B54), and when adding back GFs after the respective treatment times for 4 days (B7 + GF4 and B54 + GF4) (n = 4–7
mice in each group). Scale bars, 100 mm.likely include enhancer elements. Those loci that failed to
be silenced in G26 B8 were identified by the intersection
of differentially more accessible loci in NS cells versus
BMP-differentiated progeny shared with loci more acces-
sible in the BMP-treated GNS cells versus BMP-treated NS
cells. This analysis identified 268 loci (Figure 6B).
We used the Genomic Regions Enrichment of Annota-
tions Tool (GREAT) to identify enriched genes associated
with these regions. The top identified Kyoto Encyclopedia
of Genes and Genomes (KEGG) category was glioma836 Stem Cell Reports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 Thepathways (genes CAMK2B, CAMK2D, CALM1, IGF1, and
PIK3R1). Several other cell-cycle regulators also were identi-
fied (Figure 6B).We determinedwhich transcription factor-
bindingmotifs were overrepresented in these loci and iden-
tified many binding motifs associated with SOX proteins
(Table S1). Motifs for many developmental transcription
factors, such as those of the SOX, GATA, POU, and FOX
families, were enriched. These included motifs for SOXB1
family members, most notably the critical NS cell self-
renewal factor SOX2 (Figure 6D). Together these dataAuthors
Figure 6. ATAC-Seq Analysis of BMP4-Treated G26 and NS-1 Cells
(A) PCA plot shows ATAC-seq data.
(B) Heatmap generated for those loci that failed to be closed during BMP-induced differentiation in G26 compared to normal NS cells. KEGG
glioma gene proximal loci (<10 kb) are labeled in red; cell-cycle genes in blue are the shared glioma cell-cycle loci in black.
(C) Genome browser view of the IGF1 glioma locus is shown.
(D) Motif enrichment analysis identified a high frequency of SOX motifs within those peaks identified in (B); two top motifs (lowest
adjusted p values) for SOX2 are shown (see also Table S1 for full motif sets).suggest that increased levels and/or activity of SOX pro-
teins could undermine the ability of GNS cells to exit self-
renewal.
GNS Cell-Derived Oligodendrocyte Cells Fail to
Undergo Terminal Cell-Cycle Arrest and Are Able to
De-differentiate
Oligodendrocyte differentiation of GNS cells might pro-
vide an alternative possibility for successful differentiation
therapy for GBM. The cell surface marker O4 defines a
pre-oligodendrocyte cell state, while MBP defines a more
mature myelinating state (Zhang, 2001). Building on our
previous studies (Pollard et al., 2009), we identified a subset
of GNS cells (G144, G25, and G2) that could readilyStem Cell Rgenerate O4-expressing oligodendrocyte-like cells by the
removal of GFs (Figures 7A–7C). O4-expressing cells
emerge several days following GF withdrawal, acquire an
elaborate oligodendrocyte-like branched morphology,
and are non-proliferative when assessed by EdU incorpora-
tion (Figure 7A). Our qRT-PCR confirmed that MBP and
MAGwere activated (Figure 7D); however, by immunocyto-
chemistry we found that MBP, a more mature oligodendro-
cyte marker, was expressed only in a handful of the O4-
expressing cells, suggesting themajority of cells fail to fully
mature (data not shown). Consistent with this, upon rein-
troduction of GFs for 4 days, it was clear that, similar to the
BMP-induced astrocytes, the O4-positive cells remained
competent to re-enter cell cycle (Figure 7E).eports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 The Authors 837
Figure 7. Oligodendrocyte-like Cells Generated from GNS Cells Fail to Terminally Differentiate
(A) G144 cells stained with O4 (red) and EdU under self-renewal conditions (+GF) and under differentiating conditions (GF withdrawal,
GF) (left) and flow cytometry (right) are shown.
(B) Live O4 immunostaining in G19, G25, and G144 after GF withdrawal for 7 days is shown (green).
(C) Quantitation of flow analysis from (B). Error bars denote SD of biological replicates (n = 3–7).
(D) The qPCR analysis of the oligodendrocyte markers MBP and MAG. Error bars denote SD of biological and technical duplicates.
(E) EdU incorporation in proliferating G26 (left), after 10 days GF withdrawal (middle), and at re-exposure to EGF and FGF-2 (GF) (right).
Quantification shows the same experiment and additional experiments at 20 days (six biological replicates).
(F) (Top) Experimental design for clonal analysis of differentiation commitment in O4-positive cells. (Bottom) Live immunostaining of O4
in the G144 culture after GF withdrawal (left), at single-cell deposition (middle), and after adding back GFs (right) is shown.
(G) Quantification of O4-positive cells after single-cell deposition indicates that O4-positive cells can re-enter cell cycle and proliferate.
Total number of cells in each well was scored after 10 days of GF re-addition. Undifferentiated controls, UD; cell death, cross. Scale bars,
100 mm.A significant reduction in the numbers of O4-positive
cells was observed after only 48 hr of GF re-exposure, sug-
gesting that the majority of O4 cells might be quickly re-
verting to the GNS state by de-differentiation. To test this
directly, wemade use of the fact that O4 is a live cell surface
marker amenable to fluorescence-activated cell sorting
(FACS), enabling single-cell isolation and clonal analysis
(Figures 7F and 7G). We harvested the highest 1% O4-ex-838 Stem Cell Reports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 Thepressing subpopulation after 8 days of differentiation by
FACS and deposited single cells in eachwell of amicroplate.
Surprisingly, we found that O4-expressing cells are able
to readily re-enter cell cycle with similar frequency to
O4-negative cells (both G144 and G25) (Figure 7G).
Together these data demonstrate that, similar to astrocyte
differentiation, oligodendrocyte-like cells generated from
GNS cell differentiation do not readily undergo terminalAuthors
differentiation and permanent cell-cycle arrest and remain
vulnerable to de-differentiation.DISCUSSION
GBM-derived stem cells previously have been reported to
differentiate in response to BMPs and to acquire a non-ma-
lignant astrocyte-like phenotype (Piccirillo et al., 2006). For
differentiation therapy to be effective for GBM, it will be
important to attain terminal cell-cycle arrest, both because
of the nature of the disease (tumor cells widely disseminate
through the brain by infiltration) and because of the nature
of the differentiated cell types (neurons, oligodendrocytes,
and astrocytes), which unlike tissues with a rapid cellular
turnover are long-lived. Here we assessed the capacity of
humanGBM-derived stem cells to undergo appropriate ter-
minal astrocyte and oligodendrocyte differentiation. Our
findings suggest inter-tumoral heterogeneity in cytostatic
differentiation responses, and a limited scope for proper
epigenetic resetting could limit the effectiveness of differ-
entiation therapy for GBM.
We first explored whether GBM stem cells derived from
independent tumors would all respond similarly. Striking
differences were observed among the distinct patient-
derived GNS cell lines, with a spectrum of outcomes
ranging from a full cytostatic response to lack of any
phenotypic change following exposure to BMP4. It is likely
that these differential responses in vitro would be mirrored
by patient responses in a clinical setting and that only a
subset of patients might respond to BMP4 differentiation
therapy. Furthermore, BMP-unresponsive cells would be
likely to become enriched following treatment and subse-
quent tumor growth due to selective pressures.
Second, we focused our attention on the subset of GNS
cultures in which there was a strong cytostatic response
(G26 and G19) and assessed whether differentiation was
accompanied by reconfiguration of the epigenetic land-
scape (DNA methylation) in a manner similar to geneti-
cally normal NS cells. We found that one patient line
(G26 cells) indeed responded with a significant number
of reconfigured loci, including those of known importance
to neuronal and glial differentiation. However, these re-
sponses were delayed, and RNA-seq analysis revealed that
the expression of many genes controlling the cell cycle/
DNA replication licensing apparatus was not extinguished.
More significantly, for another cell line (G19), despite a
uniform exit from cell cycle and upregulation of GFAP,
we did not observe any striking changes in DNA methyl-
ation patterns. Thus, even in the two GNS cell lines that
underwent BMP-induced cell-cycle exit, there was incom-
plete epigenetic progression associated with astrocyte
differentiation.Stem Cell RThird, we tested the permanence of cell-cycle exit for
both post-mitotic astrocytes and oligodendrocytes derived
from the GNS cells. Although cells were initially overtly
differentiated, they remained immediately responsive to
re-exposure to EGF and FGF-2 and began proliferating.
This rapid re-entry into cell cycle was unexpected, as these
cells had striking morphological changes and molecular
markers of differentiation, and they were kept in a non-
cycling state for many weeks or months (for astrocytes).
Clearly, a latent ability to re-enter a cycling state is not
desirable for any prospective differentiation therapy. It is
possible that the combination of BMP and increased cell-
autonomous EGF/FGF signaling (due to genetic pathways)
within GNS cells forces them into a quiescent astrocyte
stem cell state, rather than triggering terminal astrocyte
differentiation (Martynoga et al., 2013). Moreover, our
GNS cell cultures may have been heterogeneous in their
response to BMP, with subsets of cells primed to becoming
quiescent astrocyte-like stem cells (type B cells), while
others were driven to being differentiated astrocytes.
However, pervasive cell-cycle re-entry was observed upon
re-exposure to GFs, suggesting that neither cell state had
undergone proliferative arrest. Better markers that distin-
guish GFAP-expressing astrocyte stem cells from paren-
chymal differentiated astrocytes will be needed to study
this further. Determining the molecular pathways that
control reactivation of dormant or quiescent stem cells
will be an important issue to resolve, as these may include
new therapeutic targets.
Mapping of chromatin accessibility before and after BMP
treatment in both NS cells and GNS cells enabled us to
identify SOX-enriched regulatory regions as loci that were
failing to be silenced appropriately in GNS cells. This offers
a potential mechanistic explanation for the susceptibility
to de-differentiation or acquisition of a quiescent astrocyte
stem cell phenotype. SOX2 is a clear candidate for the spe-
cific factor that could be involved. It is a pioneer factor
necessary for NS cell self-renewal that is amplified in a sub-
set of GBMs (Brennan et al., 2013). Whether it is the
increased activity or levels of SOX proteins or some of the
other developmental transcription factors we identified
that limit differentiation will be an interesting question
to explore in the future.
Our observations challenge the simple notion that the
exit from cell cycle and acquisition of differentiated fea-
tures is indicative of terminal differentiation and an irre-
versible exit from cell cycle. The finding that both NS and
GNS cells takemanyweeks ormonths to accumulate signif-
icant changes in DNAmethylation was surprising, and it is
in stark contrast to similar analyses carried out in the he-
matopoietic system where many thousands of MVPs occur
rapidly (in days). This may reflect contrasting time frames
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associated with their physiological demands during
embryogenesis (i.e., human CNS continues its maturation,
plasticity, and growth for many years postnatally, whereas
hematopoietic cell types are needed urgently for embryo
and postnatal viability and they turn over rapidly). Clearly,
if differentiation commitment and terminal cell-cycle ar-
rest are underlain by epigenetic mechanisms that operate
over the course of many weeks or months, this should to
be taken into account in the design of any therapeutic
approach.
There is little evidence that NS cells generate progeny via
a deep hierarchy, i.e., a series of multiple restricted progen-
itors and precursors (Rowitch and Kriegstein, 2010). This
means differentiated glial cells might be especially vulner-
able to re-acquiring features of their more primitive ances-
tors, as several stepwise de-differentiation events would not
be required. Indeed, we found following transplantation
that BMP-treated GNS cultures remained capable of initi-
ating tumors.
A caveat of our study is that differentiation was assessed
in vitro. Whether the high levels of EGF and FGF to which
we re-exposed differentiated cells would be encountered
in vivo is not clear. However, genetic activation/amplifica-
tion of EGFR- and FGFR-signaling pathways are hallmarks
of the molecular pathology of GBM, and, therefore, sus-
tained high levels of cell-autonomous signaling will be
frequent across patient populations. Our study highlights
the caution that must be exerted when assuming that
non-cycling cells with differentiated features are terminally
differentiated. In the future, use of in vivo genetic fate
mapping of the behavior of the differentiated progeny of
tumor-initiating cells will help shed light on this issue.
Suva` et al. (2014) recently have explored the transcrip-
tional circuits that correlate with the GBM stem cell state
versus serum-cultured astrocyte progeny that are non-ma-
lignant. The inductive signals specific to serum that limit
tumor initiation remain unclear. However, these cells
were still proliferative in serum and were cultured long
term before tumor initiation potential and molecular
characterization were performed, which may risk in vitro
selection of acquired genetic changes that adapt cultures
to serum.
The focus of our study has been on primary GBM. It will
be important to explore whether differentiation therapy
might have value for other forms of glioma, particularly
those that are driven by mutations in core epigenetic regu-
lators, such as pediatric high-grade glioma (Wu et al., 2012;
Schwartzentruber et al., 2012), ependymoma (Mack et al.,
2014), and medulloblastoma (Parsons et al., 2011). How-
ever, the genetic drivers that have been uncovered in these
forms of brain tumors include direct genetic disruptions
to the epigenetic memory machinery (e.g., inhibition of
PRC2 byH3.3mutations in pediatric glioma, IDH1/2muta-840 Stem Cell Reports j Vol. 5 j 829–842 j November 10, 2015 j ª2015 Thetions, and associated CpG hypermethylator phenotypes
for secondary GBM). Thus, the potential for brain tumor
stem cells to be permanently driven to a differentiated
and non-proliferative state may well be limited.
Our findings highlight inter-tumoral heterogeneity,
aberrant changes in DNA methylation patterns, and
vulnerability to de-differentiation as major challenges to
the effectiveness of differentiation to robustly suppress
tumor cell proliferation in primary GBM.EXPERIMENTAL PROCEDURES
Cell Culture
Briefly, GNS and NS cell lines were propagated under identical cul-
ture conditions using adherent culture on laminin substrate in the
presence of EGF and FGF-2, as described previously (Pollard, 2013;
Sun et al., 2008). Human NS cells were those used in the study by
Danovi et al. (2013) and designated 11130. GNS cell lines G144,
G166, G179, and GliNS2 have been described previously (Pollard
et al., 2009). Remaining lines were generated as described by Fael
Al-Mayhani et al. (2009). ForDNAmethylation analysis, T75 flasks,
pre-coated with laminin (10 mg/ml), were seeded with four million
cells. Biological duplicates were used with independent cultures.
Then 24 hr later, cells were washed with PBS and replaced with
media containing BMP4 (20 ng/ml, Sigma-Aldrich), but no EGF
or FGF-2. Differentiation media, containing BMP, was replaced
every 8 days throughout the time course and supplemented with
fresh BMP at 4 days. All samples were stored at 80C and pro-
cessed in parallel.
Cell Proliferation Analysis
Cells were counted using the Vi-CELL automated cell counter
(BeckmanCoulter Genomics). Triplicatewells were used (two inde-
pendent experiments). EdU incorporation assays were performed
using the Click-iT EdU Alexa Fluor 488 Imaging Kit (Invitrogen).
Cells were grown in 96-well plates and pulsed with (10 mM) EdU
for 16 hr prior to fixing in 4% paraformaldehyde.
Immunocytochemistry
Primary antibodies (GFAP monoclonal mouse antibody, Sigma-Al-
drich G3893, 1:1,000; rabbit OLIG2, Chemicon AB9610, 1:300)
were incubated overnight at 4C. O4 staining was performed on
live cells (O4 hybridoma). Goat secondary antibodies conjugated
to Alexa dyes (Molecular Probes) were added at 1:1,000 for 1 hr
at room temperature and DAPI was used as a nuclear counterstain.
DNA Extraction and Bisulfite Modification
DNA extraction was performed using the DNeasy Blood & Tissue
Kit (QIAGEN), including an RNA removal step. DNA (500 ng)
was used for bisulfite modification using the EZ DNA methylation
kit (D5001, Zymo Research).
DNA Methylation Data Bioinformatics Analysis
The bisulfite-modified DNA was applied to the Infinium Human-
Methylation450 BeadChips (Illumina) as previously describedAuthors
(Stricker et al., 2013). The data generated by the BeadStudio
software were exported and further analyses were performed in
R. The R package ChAMP was used for normalization and MVP
calling (Morris et al., 2014).
TCGA datasets were used to generate a GBM methylation set
of MVPs by comparing to Pilocytic astrocytoma from GEO:
GSE44684 and FACS-sorted human brain orbitofrontal cortex
(nonneuronal) from GEO: GSE50798. CIMP+ cases were excluded
since they harbor a specific methylation profile.Quantitative Real-Time RT-PCR
Total RNA was extracted with the RNeasy Mini Kit (QIAGEN),
including a genomic DNA removal step. cDNA was generated
from 1 mg mRNA using Superscript III (Invitrogen). The qRT-PCR
was conducted on the ABI 7300 (Applied Biosystems), with the
Universal Probe Library system (Roche) or using TaqMan gene
cards (Applied Biosystems). The reactions were carried out in
technical duplicates on biological replicates.Gene Expression and Subtyping Analysis
Exon arrays were processed using v1.28 of the xps Bioconductor
package normalized using the Robust Multi-chip Average (RMA)
method (Irizarry et al., 2003), and probe sets were summarized
by median polish in xps. Additional details are provided in the
Supplemental Experimental Procedures.RNA-Seq
RNA quality was assessed using a Bioanalyzer (Agilent Technolo-
gies) and all RNA integrity number (RIN) values were above 9.4.
The mRNA was isolated with the NEBNext Poly(A) mRNA
Magnetic Isolation Module (New England Biolabs), and libraries
were prepared with NEBNext mRNA Library Prep Master Mix Set
for Illumina (NEB). Samples were multiplexed with seven or eight
samples per sequencing lane (samples indexed with NEBNext
Multiplex Oligos for Illumina). Samples were run in biological
duplicates and sequenced in 100-bp paired-end format. RNA-seq
data were processed using RSEM (v1.2.0) (Li and Dewey, 2011).
The BioConductor package DESeq was used to detect differential
expression (Anders and Huber, 2010).ATAC-Seq
ATAC library preparation was undertaken according to published
protocols (Buenrostro et al., 2013). Eight libraries were derived
from cell lines NS-1 and G26, in EGF/FGF and BMP, in biological
replicates. Additional details are provided in the Supplemental
Experimental Procedures.Xenotransplantation
GNS cells, proliferating, BMP4 treated, or BMP4 treated and subse-
quently cultured in EGF and FGF-2 for 4 days (BMP4 + GF), were
detached with Accutase, and 50,000 GNS cells were diluted
in 1 ml PBS and injected using a stereotaxic frame into 10- to
20-week-old NOD/SCID striatum (Pollard et al., 2009). Animals
were maintained and used in a designated facility under licenses
issued and approved by the UK Government Home Office.Stem Cell RACCESSION NUMBERS
The accession numbers for the data reported in this paper are
ArrayExpress: E-MTAB-3864, E-MTAB-3867, and E-MTAB-3868.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2015.09.014.
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